ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

ClinicalTrials.gov ID: NCT03110562

Public ClinicalTrials.gov record NCT03110562. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Study identification

NCT ID
NCT03110562
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Enrollment
402 participants

Conditions and interventions

Interventions

  • Bortezomib Drug
  • Dexamethasone Drug
  • Selinexor Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 23, 2017
Primary completion
Feb 17, 2020
Completion
May 11, 2022
Last update posted
Aug 20, 2024

2017 – 2022

United States locations

U.S. sites
20
U.S. states
17
U.S. cities
19
Facility City State ZIP Site status
Boca Raton Clinical Research (BRCR) Medical Center Plantation Florida 33324
Emory University Atlanta Georgia 30322
Kaiser Permanente Hawaii Honolulu Hawaii 96817
McFarland Clinic Ames Iowa 50010
Stormont Vail Health Care (Cotton O'Neil Cancer Center ) Topeka Kansas 66606
Commonwealth Hematology Danville Kentucky 40422
Norton Cancer Institute Louisville Kentucky 40202
University of Maryland Baltimore Maryland 21201
Central Care Cancer Center Bolivar Missouri 65613
The Valley Hospital Luckow Pavilion Paramus New Jersey 07652
Mount Sinai New York New York 10029
The Cancer Institute at St. Francis Hospital Roslyn New York 11576
Novant-Forsyth Memorial Hospital Winston-Salem North Carolina 27103
University of Cincinnati Health Cincinnati Ohio 45267
Southwest Cancer Center of Oklahoma Lawton Oklahoma 73505
Kaiser Permanente Northwest OR Portland Oregon 97210
SCOR AnMed Health Cancer Center Anderson South Carolina 29621
Prairie Lakes Healthcare Watertown South Dakota 57201
Baylor Sammons Cancer Center Dallas Texas 75246
University of Texas Southwestern Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03110562, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2024 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03110562 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →